


The Early Detection Initiative

An Impact Report

Prepared for Sky Foundation

December 18, 2019



No one wants to hear the words, “You have cancer.” Though, when a doctor follows up with, “but we caught it early,” the patient is given words of hope and empowerment.

Colon, breast and other types of cancers can be detected early through screenings. When caught early and localized, the five-year survival rate for colorectal cancer is 90 percent; for breast cancer, 99 percent. Almost 40 percent of colon cancer patients and 62 percent of breast cancer patients are diagnosed in the early and localized stage.

Only 10 percent of pancreatic cancer patients are diagnosed at the early and localized stage.

Unfortunately, unlike colon, breast and other cancers people can be regularly screened for, there are no specific tests that easily and dependably find early-stage pancreatic cancer in people who are not experiencing symptoms. More than half of pancreatic cancer patients are diagnosed in the later stages, when surgery is no longer an option and the cancer has spread to distant parts of the body.

Early detection, screening and diagnosis have been proven to significantly improve patient survival rates and quality of life.

Sheila, your support of the Early Detection Initiative (EDI) has moved the research field forward and toward improved outcomes for pancreatic cancer patients. I hope you see the impact your gift has made and the progress we were able to make because of you.

When We Last Updated You

When we gave you an update in April 2019 on the impact of your gift, we shared four major milestones that were made possibly because of your generosity.

With your help:

- The EDI Trial Design was approved in January 2019 by the EDI Steering Committee
- Individuals were enrolled across eight sites for the New Onset Diabetes (NOD) protocol, the first step in enrolling for the EDI protocol.
- Experts from PanCAN, the National Cancer Institute, the American Diabetes Association and major research institutes like the Mayo Clinic came together to standardize protocols for enrollment.
- We got ready to enroll patients into the EDI study in summer 2019.

Since Then

Since we last updated you, a lot has happened.

The EDI has created a screening process to proactively find patients' pancreatic cancer — possibly years before it would have otherwise been discovered. As a result, we estimate that many more people will be able to receive surgery, a key treatment that can lead to a significant eight-fold increase in survival. This important initiative has gained ground this year because of your generosity.

Since the population eligible to participate in study is small, it's essential to capitalize on every approach to increase enrollment.

We're now able to offer the study to non-English speaking patients so we can further expand the eligible population. This is key – when more patients can participate, we can accelerate our learnings. Our newly redesigned patient marketing materials will facilitate greater patient recruitment into the study.

As a result, we've enrolled more than 200 patients in the NOD study at 14 sites across the country: Kaiser Permanente Southern California, Kaiser Permanente Northern California, Cedars-Sinai Medical Center, Stanford University, University of Florida, Indiana University, St. Joseph Mercy Health System, Mayo Clinic, Ohio State University, University of Pittsburgh, and Baylor College of Medicine.

To improve even more patient outcomes, the EDI trial design is being further refined as we partner with a core group of top research investigators at institutions including MD Anderson, National Cancer Institute, Fred Hutchinson Cancer Research Center, Kaiser Permanente Northern California and Kaiser Permanente Southern California.

The study protocol includes:

- a risk-prediction model that evaluates risk based on the patient's age, weight and blood glucose levels
- clinical imaging in a subset of patients at higher risk of developing pancreatic cancer
- biospecimen collection to facilitate biomarker validation for a blood-based biomarker

The most exciting news is our planned EDI launch in Spring 2020!

We Are So Grateful

Because of your generosity, we are seeing progress being made like never before. We are incredibly grateful that the Sky Foundation understood the need and took action so that one day pancreatic cancer can be detected early.

Thank you for being a true visionary. We are at the tipping point to change the course of pancreatic cancer, and you have stood by our side along the way.

Your passionate commitment as a trailblazer in the pancreatic cancer community will change the lives of patients, their loved ones, and each person who has been touched by this terrible disease. We wouldn't be able to do the work we do without the support of thoughtful philanthropists and we're so incredibly appreciative of the relationship we've built with you.
